Corcept Therapeutics Incorporat
CORT
Positions held
Your positionsCORT isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Corcept Therapeutics operates in a competitive biotechnology sector with a strong focus on innovative treatments for metabolic and psychiatric disorders, positioning itself well against rivals.
- In Q2 2026, Corcept reported a revenue increase of 55% compared to the previous quarter, reaching $256 million.
- The company's gross margin improved to 98.4%, up from 98.3% in the prior quarter.
- Despite its strong growth, Corcept's trailing P/E ratio is significantly high at 265.71, indicating potential overvaluation.
- In Q1 2026, Corcept experienced a negative operating margin of -30.08%, reflecting operational challenges.
- The company's operating income was only $4.487 million in Q4 2025, highlighting concerns about profitability.
Fundamentals
| Market cap | $12.81B | Enterprise value | $12.52B | Trailing P/E | 263.42 | Forward P/E | 26.93 |
| PEG | 0.81 | Price / book | 18.13 | Beta | 0.40 | Dividend yield | 0.00% |
| Revenue growth | 31.7% | Earnings growth | 24.1% | Gross margin | 98.3% | Operating margin | 16.1% |
| Profit margin | 6.6% | ROE | 8.2% | ROA | 0.5% | Debt / equity | 0.01 |
| Current ratio | 2.86 | Free cash flow | $77.40M | Analyst recommendation | buy | Mean target | $141.00 |
| 52w high | $126.38 | 52w low | $28.66 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $256M | $165M | $202M | $208M | $194M | — |
| Op margin | 16.1% | -30.1% | 2.2% | 4.9% | 13.7% | — |
| Net income | $43.0M | -$31.8M | $24.3M | $19.7M | $35.1M | — |
| Gross margin | 98.4% | 98.3% | 98.7% | 97.8% | 98.2% | — |
| Gross profit | $252M | $162M | $200M | $203M | $191M | — |
| Operating income | $41.3M | -$49.6M | $4.5M | $10.2M | $26.7M | — |
- Revenue +55% vs prior quarter ($256M vs $165M).
- Gross margin 98.4% (was 98.3% prior quarter).
- Operating margin expanded to 16.1%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $761M | $675M | $482M | $402M | — |
| Op margin | 5.9% | 20.3% | 22.2% | 28.0% | — |
| Net income | $99.7M | $141M | $106M | $101M | — |
| Gross margin | 98.3% | 98.4% | 98.7% | 98.7% | — |
| Gross profit | $748M | $664M | $476M | $396M | — |
| Operating income | $44.8M | $137M | $107M | $113M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-06 · Corcept, IBD Stock Of The Day, Setting Up Amid Booming Earnings Growth
2026-10-06 · 3 Reasons to Sell CORT and 1 Stock to Buy Instead
2026-10-06 · Corcept Therapeutics Insider Sold Shares Worth $2,906,601, According to a Recent SEC Filing
2026-10-06 · Corcept Therapeutics Insider Sold Shares Worth $1,160,731, According to a Recent SEC Filing
2026-10-05 · The Zacks Analyst Blog Highlights Abbott, Corcept, Precigen and Bausch Health Companies
2026-10-02 · 4 Low-Beta Healthcare Stocks to Buy Amid Fears of Another Rate Hike
2026-09-29 · Is Aspen Pharmacare (APNHY) Stock Outpacing Its Medical Peers This Year?
2026-09-25 · Strong Commercial Execution and Pipeline Opportunities Propel Corcept Therapeutics (CORT)
2026-09-23 · Corcept Announces Planned Leadership Transition
2026-09-22 · Corcept Therapeutics (CORT) CHMP Backing Keeps Undervalued Narrative In Focus
2026-09-22 · 3 of Wall Street’s Favorite Stocks We Keep Off Our Radar
2026-09-22 · Corcept’s (CORT) Cancer Drug Just Cleared Europe’s Toughest Hurdle
Price (daily)
Full chart · RSI · MACD · patterns